Article

EyeCon 2022: Emerging therapies in geographic atrophy

Rishi Singh, MD, of Cleveland Clinic Florida, touches upon the various advancements that are making a difference for clinicians and patients and reducing their progression in this disease state.

This transcript has been edited for clarity:

Hi, my name is Rishi Singh from Cleveland Clinic Florida. It's my pleasure to be here at this year's EyeCon 2022 meeting in Marco Island, Florida, with all of my friends and colleagues.

Today, I'm going to be speaking about emerging therapies in geographic atrophy. For many years, we have had great treatments for wet macular degeneration. Unfortunately, we have had to ignore the dry disease because we just didn't have therapies available.

We're learning more about the imaging techniques, the biomarkers that assure us progression in this disease state, as well as learning about the emerging therapeutics and the alternative complement pathway as well as gene therapy that are making a difference for our patients and reducing their progression of this disease state.

I'm really excited to learn more from my colleagues and friends who are also presenting on various other retinal topics, and we're going to learn a lot from this program today.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.